Logo image of BELYS.BR

BELYSSE GROUP NV (BELYS.BR) Stock Fundamental Analysis

Europe - EBR:BELYS - BE0974314461 - Common Stock

0.88 EUR
+0.04 (+4.14%)
Last: 9/12/2025, 7:00:00 PM
Fundamental Rating

3

Overall BELYS gets a fundamental rating of 3 out of 10. We evaluated BELYS against 32 industry peers in the Household Durables industry. BELYS may be in some trouble as it scores bad on both profitability and health. BELYS is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

In the past year BELYS has reported negative net income.
BELYS had a positive operating cash flow in the past year.
In the past 5 years BELYS reported 4 times negative net income.
BELYS had a positive operating cash flow in 4 of the past 5 years.
BELYS.BR Yearly Net Income VS EBIT VS OCF VS FCFBELYS.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 50M -50M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -0.02%, BELYS is doing worse than 62.50% of the companies in the same industry.
The Return On Equity of BELYS (-0.07%) is worse than 62.50% of its industry peers.
BELYS has a Return On Invested Capital (6.45%) which is in line with its industry peers.
The Average Return On Invested Capital over the past 3 years for BELYS is below the industry average of 9.97%.
Industry RankSector Rank
ROA -0.02%
ROE -0.07%
ROIC 6.45%
ROA(3y)-6.3%
ROA(5y)-7.85%
ROE(3y)-25.25%
ROE(5y)-43.19%
ROIC(3y)7.13%
ROIC(5y)5.99%
BELYS.BR Yearly ROA, ROE, ROICBELYS.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -50 -100

1.3 Margins

Looking at the Operating Margin, with a value of 6.91%, BELYS is in line with its industry, outperforming 59.38% of the companies in the same industry.
In the last couple of years the Operating Margin of BELYS has declined.
BELYS has a better Gross Margin (61.34%) than 84.38% of its industry peers.
BELYS's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 6.91%
PM (TTM) N/A
GM 61.34%
OM growth 3Y-5.23%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.7%
GM growth 5YN/A
BELYS.BR Yearly Profit, Operating, Gross MarginsBELYS.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 20 -20 40 -40 60

3

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BELYS is destroying value.
The number of shares outstanding for BELYS remains at a similar level compared to 1 year ago.
Compared to 1 year ago, BELYS has an improved debt to assets ratio.
BELYS.BR Yearly Shares OutstandingBELYS.BR Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M
BELYS.BR Yearly Total Debt VS Total AssetsBELYS.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of 0.27, we must say that BELYS is in the distress zone and has some risk of bankruptcy.
BELYS's Altman-Z score of 0.27 is on the low side compared to the rest of the industry. BELYS is outperformed by 87.50% of its industry peers.
The Debt to FCF ratio of BELYS is 5.07, which is a neutral value as it means it would take BELYS, 5.07 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 5.07, BELYS is in the better half of the industry, outperforming 71.88% of the companies in the same industry.
A Debt/Equity ratio of 1.80 is on the high side and indicates that BELYS has dependencies on debt financing.
BELYS's Debt to Equity ratio of 1.80 is on the low side compared to the rest of the industry. BELYS is outperformed by 93.75% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.8
Debt/FCF 5.07
Altman-Z 0.27
ROIC/WACC0.59
WACC10.92%
BELYS.BR Yearly LT Debt VS Equity VS FCFBELYS.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

BELYS has a Current Ratio of 1.63. This is a normal value and indicates that BELYS is financially healthy and should not expect problems in meeting its short term obligations.
BELYS has a Current ratio (1.63) which is comparable to the rest of the industry.
A Quick Ratio of 0.90 indicates that BELYS may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.90, BELYS is in line with its industry, outperforming 46.88% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.63
Quick Ratio 0.9
BELYS.BR Yearly Current Assets VS Current LiabilitesBELYS.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 100M 200M 300M 400M

2

3. Growth

3.1 Past

The earnings per share for BELYS have decreased strongly by -100.58% in the last year.
Looking at the last year, BELYS shows a decrease in Revenue. The Revenue has decreased by -6.81% in the last year.
The Revenue has been growing slightly by 0.43% on average over the past years.
EPS 1Y (TTM)-100.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100.76%
Revenue 1Y (TTM)-6.81%
Revenue growth 3Y0.43%
Revenue growth 5YN/A
Sales Q2Q%-6.97%

3.2 Future

BELYS is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by 0.00% yearly.
Based on estimates for the next years, BELYS will show a small growth in Revenue. The Revenue will grow by 0.36% on average per year.
EPS Next Y-75%
EPS Next 2Y-32.3%
EPS Next 3Y0%
EPS Next 5YN/A
Revenue Next Year-3.57%
Revenue Next 2Y-0.54%
Revenue Next 3Y0.36%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
BELYS.BR Yearly Revenue VS EstimatesBELYS.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M
BELYS.BR Yearly EPS VS EstimatesBELYS.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 0.4 -0.4 0.6

5

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Forward Earnings ratio of 7.77, the valuation of BELYS can be described as very cheap.
78.13% of the companies in the same industry are more expensive than BELYS, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 22.73. BELYS is valued rather cheaply when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 7.77
BELYS.BR Price Earnings VS Forward Price EarningsBELYS.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, BELYS is valued cheaper than 84.38% of the companies in the same industry.
100.00% of the companies in the same industry are more expensive than BELYS, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 1.02
EV/EBITDA 3.99
BELYS.BR Per share dataBELYS.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-32.3%
EPS Next 3Y0%

0

5. Dividend

5.1 Amount

BELYS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

BELYSSE GROUP NV

EBR:BELYS (9/12/2025, 7:00:00 PM)

0.88

+0.04 (+4.14%)

Chartmill FA Rating
GICS IndustryGroupConsumer Durables & Apparel
GICS IndustryHousehold Durables
Earnings (Last)09-05 2025-09-05
Earnings (Next)10-20 2025-10-20
Inst Owners14.18%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap31.63M
Analysts84.44
Price Target1.63 (85.23%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-40%
EPS NY rev (3m)-40%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-2.17%
Revenue NY rev (3m)-2.17%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 7.77
P/S 0.12
P/FCF 1.02
P/OCF 0.77
P/B 0.39
P/tB N/A
EV/EBITDA 3.99
EPS(TTM)0
EYN/A
EPS(NY)0.11
Fwd EY12.88%
FCF(TTM)0.86
FCFY98.15%
OCF(TTM)1.14
OCFY129.25%
SpS7.52
BVpS2.28
TBVpS-0.59
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -0.02%
ROE -0.07%
ROCE 7.87%
ROIC 6.45%
ROICexc 7.62%
ROICexgc 15.63%
OM 6.91%
PM (TTM) N/A
GM 61.34%
FCFM 11.48%
ROA(3y)-6.3%
ROA(5y)-7.85%
ROE(3y)-25.25%
ROE(5y)-43.19%
ROIC(3y)7.13%
ROIC(5y)5.99%
ROICexc(3y)9.09%
ROICexc(5y)7.47%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)8.69%
ROCE(5y)7.3%
ROICexcg growth 3Y21.04%
ROICexcg growth 5YN/A
ROICexc growth 3Y8.96%
ROICexc growth 5YN/A
OM growth 3Y-5.23%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.7%
GM growth 5YN/A
F-Score4
Asset Turnover0.9
Health
Industry RankSector Rank
Debt/Equity 1.8
Debt/FCF 5.07
Debt/EBITDA 3.85
Cap/Depr 50.25%
Cap/Sales 3.64%
Interest Coverage 1.3
Cash Conversion 106.91%
Profit Quality N/A
Current Ratio 1.63
Quick Ratio 0.9
Altman-Z 0.27
F-Score4
WACC10.92%
ROIC/WACC0.59
Cap/Depr(3y)58.36%
Cap/Depr(5y)60.35%
Cap/Sales(3y)3.69%
Cap/Sales(5y)3.85%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-100.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100.76%
EPS Next Y-75%
EPS Next 2Y-32.3%
EPS Next 3Y0%
EPS Next 5YN/A
Revenue 1Y (TTM)-6.81%
Revenue growth 3Y0.43%
Revenue growth 5YN/A
Sales Q2Q%-6.97%
Revenue Next Year-3.57%
Revenue Next 2Y-0.54%
Revenue Next 3Y0.36%
Revenue Next 5YN/A
EBIT growth 1Y-18.87%
EBIT growth 3Y-4.83%
EBIT growth 5YN/A
EBIT Next Year86.36%
EBIT Next 3Y25.99%
EBIT Next 5YN/A
FCF growth 1Y111.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y49.84%
OCF growth 3YN/A
OCF growth 5YN/A